Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study.-MedSci.cn

Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): Results from one cohort of an ongoing phase 2 study.

Xu, N; Yuan, XL; Wang, BH; Bai, YX; Li, EX; Li, YY; Wang, HL; Xu, JM

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (4):

科室
- - 订阅+
  - 更多科室
工具
服务